Efficacy of platinum/pemetrexed combination chemotherapy in ALK-positive non-small cell lung cancer refractory to second-generation ALK inhibitors

BACKGROUND: The current standard initial therapy for advanced ALK-positive non-small cell lung cancer (NSCLC) is a second-generation ALK tyrosine kinase inhibitor (TKI) such as alectinib. The optimal next-line therapy after failure of a second-generation ALK TKI remains to be established; however, s...

Full description

Saved in:
Bibliographic Details
Published in:J Thorac Oncol
Main Authors: Lin, Jessica J., Schoenfeld, Adam J., Zhu, Viola W., Yeap, Beow Y., Chin, Emily, Rooney, Marguerite, Plodkowski, Andrew J., Digumarthy, Subba R., Dagogo-Jack, Ibiayi, Gainor, Justin F., Ou, Sai-Hong Ignatius, Riely, Gregory J., Shaw, Alice T.
Format: Artigo
Language:Inglês
Published: 2019
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7058505/
https://ncbi.nlm.nih.gov/pubmed/31669591
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jtho.2019.10.014
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items